AtriCure launches the AtriClip FLEX•V device in the United States

714

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, has announced that it has launched the AtriClip FLEX•V Left Atrial Appendage (LAA) Exclusion System in the United States. The new AtriClip FLEX•V is the first device of the AtriClip family to offer a clip deployment trigger release. The device also offers an open-ended AtriClip design combined with a tip-first closure mechanism to enable easier navigation and placement in cardiac surgeries. This “V” clip technology builds off the AtriClip PRO•V, which was launched in September of 2017 for minimally-invasive surgery applications. The AtriClip FLEX•V received 510(k) clearance in January of 2018.

In 2010, AtriCure became the first company to receive clearance for a left atrial appendage management device. Since then, over 125,000 AtriClip devices have been sold worldwide. With new innovations and technology, AtriCure continues to increase left atrial appendage management and enhance open-concomitant cardiac surgery to help patients worldwide.

“The AtriClip FLEX•V is an exciting new product that we are pleased to be releasing to our U.S. customers,” said Mike Carrel, president, and CEO of AtriCure. “This product will enable easier AtriClip deployment in open-chest surgeries, as it combines the lower-profile “V” Clip technology with a redesigned handle enabling a one-handed operation of the device. To date, we have successfully placed over 200 AtriClip PRO•V devices since we launched in September of 2017, and this innovation builds off that momentum. We are excited to see how many more patients we can impact with the addition of the AtriClip FLEX•V to the AtriClip franchise.”

The AtriClip FLEX•V has a rotatable and malleable shaft allowing cardiac surgeons and hospital staff to adjust the AtriClip to adapt to specific patient anatomies. In addition, the new clip opening handle offers a reduced fatigue design to reposition the AtriClip multiple times before deployment to ensure the device is extended beyond the LAA and at the base.

To date, AtriClip products are the most widely sold LAA management device worldwide with more than 125,000 implanted.

(Visited 108 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here